血生成预测突破性出血在获得的血友病A患者在埃米齐祖马布预防治疗下
Fabius J Pelzer1, Ella I Ertekin1, Olga Oleshko1
1Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover.
Haematologica
|November 13, 2025
概括
血生成试验 (TGA) 可以监测获得的血友病A (AHA) 中的埃米齐祖马布的疗效. 较高的TGA结果与在艾米齐祖马布预防治疗的AHA患者中降低出血风险相关.
科学领域:
- 血液学 血液学 血液学
- 凝血障碍 凝血障碍 凝血障碍
- 药理动力学是什么 药理动力学
背景情况:
- 获得性血友病A (AHA) 是一种罕见的出血疾病,由对凝血因子VIII (FVIII) 的自身抗体引起.
- 埃米齐祖马布是一种双特异性抗体,取代FVIIIa活动,但可能发生突破性出血.
- 监测埃米齐祖马布的疗效对于管理AHA患者至关重要.
研究的目的:
- 调查AHA患者中血栓生成试验 (TGA) 和埃米齐祖马布水平,FVIII活性和其他凝血因子之间的关系.
- 为了确定TGA是否可以预测埃米齐祖马布预防期间突破性出血事件.
主要方法:
- 来自GTH-AHAEMI研究的患者样本的分析,以前性评估艾米齐祖马布治疗的AHA患者的出血风险.
- 使用校准自动血小板测定 (TF-TGA和FXIa-TGA) 来测量血小板生成.
- 与埃米齐祖马布水平,FVIII活性和出血发生率相关的TGA参数.
主要成果:
- 因子XIa启动的TGA (FXIa-TGA) 峰值血栓生成与埃米齐祖马布水平和残留FVIII活性正相关.
- 在FXIa-TGA中产生更高的峰值血栓生成与显著减少的出血事件率有关 (IRR 0.40 [0.17-0.84]).
结论:
- TGA,特别是FXIa-TGA,可以作为一种有价值的工具,用于监测在获得的血友病A.艾米齐祖马布的疗效.
- 血栓生成水平可能会预测接受埃米齐祖马布预防治疗的患者突破性出血的风险.
更多相关视频
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Venous Thrombosis III: Interprofessional Care
271
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
271
Disorders of Hemostasis
2.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.0K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
Extrinsic and Intrinsic Pathways of Hemostasis
11.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.9K
Venous Thrombosis IV: Nursing Management
190
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
190


